

# Accepted Manuscript

Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia

Tamio Teramoto, MD, PhD, Hiroyuki Daida, MD, Katsunori Ikewaki, MD, PhD, Hidenori Arai, MD, PhD, Yuko Maeda, MS, R.Ph, Mariko Nakagomi, MS, RPh, Masayoshi Shirakawa, MA, MS, Yuichiro Watanabe, MS, RPh, Taro Kakikawa, MS, RPh, Hirotaka Numaguchi, MD, PhD, Amy O. Johnson-Levonos, PhD, Robert O. Blaustein, MD, PhD



PII: S0021-9150(17)30100-4

DOI: [10.1016/j.atherosclerosis.2017.03.009](https://doi.org/10.1016/j.atherosclerosis.2017.03.009)

Reference: ATH 14984

To appear in: *Atherosclerosis*

Received Date: 1 December 2016

Revised Date: 2 March 2017

Accepted Date: 6 March 2017

Please cite this article as: Teramoto T, Daida H, Ikewaki K, Arai H, Maeda Y, Nakagomi M, Shirakawa M, Watanabe Y, Kakikawa T, Numaguchi H, Johnson-Levonos AO, Blaustein RO, Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia, *Atherosclerosis* (2017), doi: 10.1016/j.atherosclerosis.2017.03.009.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Lipid-modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Japanese Patients with Dyslipidemia**

Tamio Teramoto,<sup>a</sup> MD, PhD, Hiroyuki Daida,<sup>b</sup> MD, Katsunori Ikewaki,<sup>c</sup> MD, PhD, Hidenori Arai,<sup>d</sup> MD, PhD, Yuko Maeda,<sup>e</sup> MS, RPh, Mariko Nakagomi,<sup>e</sup> MS, RPh, Masayoshi Shirakawa,<sup>e</sup> MA, MS, Yuichiro Watanabe,<sup>e</sup> MS, RPh, Taro Kakikawa,<sup>e</sup> MS, RPh, Hirotaka Numaguchi,<sup>e,f</sup> MD, PhD, Amy O. Johnson-Levonas,<sup>g</sup> PhD, Robert O. Blaustein,<sup>g</sup> MD, PhD

<sup>a</sup>Teikyo Academic Research Center, Teikyo University, 2-11-1, Kaga, Itabashi-ku, Tokyo, Japan; [ttera@med.teikyo-u.ac.jp](mailto:ttera@med.teikyo-u.ac.jp)

<sup>b</sup>Department of Cardiovascular Medicine, School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, Japan; [daida@juntendo.ac.jp](mailto:daida@juntendo.ac.jp)

<sup>c</sup>Division of Anti-aging and Vascular Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa-city, Saitama, Japan; [kikewaki@hotmail.com](mailto:kikewaki@hotmail.com)

<sup>d</sup>National Center of Geriatrics and Gerontology, 7-430 Morioka-cho, Obu City, Aichi, Japan; [harai@ncgg.go.jp](mailto:harai@ncgg.go.jp)

<sup>e</sup>MSD K.K, Kitanomaru Square, 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, Japan; [yuko.maeda@merck.com](mailto:yuko.maeda@merck.com); [mariko.nakagomi@merck.com](mailto:mariko.nakagomi@merck.com); [masayoshi.shirakawa@merck.com](mailto:masayoshi.shirakawa@merck.com); [yuichiro.watanabe@merck.com](mailto:yuichiro.watanabe@merck.com); [taro.kakikawa@merck.com](mailto:taro.kakikawa@merck.com); [hiro.numaguchi@gmail.com](mailto:hiro.numaguchi@gmail.com)

<sup>f</sup>Nippon Boehringer Ingelheim Co. Ltd, 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017, Japan

<sup>g</sup>Merck & Co., Inc., Kenilworth, NJ, USA; [amy\\_levonas@merck.com](mailto:amy_levonas@merck.com); [robert\\_blaustein@merck.com](mailto:robert_blaustein@merck.com)

For Submission to: *Atherosclerosis* as a 'Clinical Research Paper'

Corresponding Author:

Tamio Teramoto MD, PhD

Phone: 81-3-3964-1211, ext. 46139

Fax: 81-3-3964-8965

Download English Version:

<https://daneshyari.com/en/article/5599372>

Download Persian Version:

<https://daneshyari.com/article/5599372>

[Daneshyari.com](https://daneshyari.com)